Kornimate/medical-research-clean huggingface dataset:
palmitic acid and human microvascular function

Conditions: Microvascular Dysfunction; Microvasculature; Cardiovascular Diseases; Cardiovascular Diseases (CVD); Microvascular Health; Obesity and Overweight

Summary: the goal of this study is to learn how a supplement quercetin can affect microvascular function. participants will: * give two blood draws of 5 ml each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion researchers will compare blood vessel function of those who take estrogen supplements to those who do not.


Eligibility criteria:
inclusion criteria: * obesity (bmi\>30) * aged 18-60 years * english speaking exclusion criteria: * bmi\>60 * resting sbp ≥180 mmhg or dbp ≥ 110mmhg * pregnancy or breastfeeding. * prior history of myocardial infarction * diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension) * active mouth sores that affect the buccal mucosa.

Keywords: obesity supplement
study of brexucabtagene autoleucel (kte-x19) in participants with relapsed/refractory mantle cell lymphoma (cohort 3)

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Summary: the goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (kte-x19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (mcl).

study kte-c19-102 (nct02601313) enrolled participants with r/r mcl who have been treated with up to 5 prior regimens including a bruton's tyrosine kinase inhibitor (btki) in cohort 1 and cohort 2. however, to fulfill fda postmarketing requirement cohort 3 is added to the study. it will include participants with r/r mcl who have been treated with up to 5 prior regimens but have not received prior therapy with a btki. the primary analysis in cohort 1 and cohort 2 is already completed. data for cohort 3 will be analyzed separately. therefore, this separate registration is only for cohort 3. after the end of kte-c19-102, subjects who received an infusion of anti-cd19 car t cells will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, kt-us-982-5968

Eligibility criteria:
key inclusion criteria: * up to 5 prior regimens for mcl. prior therapy must have included anthracycline- or bendamustine-containing chemotherapy and anti-cd20 monoclonal antibody therapy. individuals must not have received prior therapy with a btki. * at least 1 measurable lesion * platelet count ≥ 75,000/ul * creatinine clearance (as estimated by cockcroft gault) ≥ to 60 cc/min * cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (echo) or multigated acquisition (muga), and no clinically significant electrocardiogram (ecg) findings * baseline oxygen saturation \> 92% on room air key exclusion criteria: * known history of infection with human immunodeficiency virus (hiv) or hepatitis b (hbsag positive) or hepatitis c virus (anti-hcv positive). individuals with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing * history of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with central nervous system (cns) involvement * presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring iv antimicrobials for management note: other protocol defined inclusion/exclusion criteria may apply.
combining emotion regulation and mindfulness skills for preventing depression relapse

Conditions: Major Depressive Disorder

Summary: in the present study researchers aim to investigate the effectiveness of an intervention combining emotion regulation and mindfulness skills in a single 10-week program. a total of 75 individuals with major depressive disorder (mdd) diagnosis in complete or partial remission participated in this randomized controlled trial (rct) comparing an intervention including emotion regulation and mindfulness skills (er+m) with a psychoeducative program. after treatment, participants were followed for a 1-year period. researchers results indicate that er+m was not more effective than the treatment used with the control group in preventing depression relapse. participants allocated to the er+m group showed a significant decrease on global psychiatric symptoms, whereas those in the control group did not. further studies are needed in order to better determine the combined effects of mindfulness and behavioral activation.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * having a former mdd diagnosis in complete or partial remission at the time of the study as indicated by the major depressive section of the structured clinical interview for dsm-iv axis i disorders (scid-i) and scores below 17 on the hamilton depression rating scale (hsrd) * having the last major depressive episode between 18 and 2 months prior to the study * having at least two previous depressive episodes * patients could continue pharmacological treatment on condition that it remained stable for at least the last two months before entering the study. exclusion criteria: * dsm-iv-tr criteria for current mdd or any other affective disorder * dsm-iv-tr criteria for alcohol or drug dependence, schizophrenia or psychotic disorders * dsm-iv-tr criteria for personality disorders; severe physical conditions such as organic brain syndrome or neurological disease; mental retardation or cognitive impairments * having received any psychotherapy including cognitive-behavioral therapy in the past * changes in the pharmacological treatment during the study.
the prediction of hemorrhage transformation by cerebral autoregulation in ais patient after endovascular thrombectomy

Conditions: Acute Ischemic Stroke; Endovascular Thrombectomy; Dynamic Cerebral Autoregulation

Summary: this observational study was designed for observe the cerebral hemodynamics and dynamic cerebral autoregulation (dca) after endovascular thrombectomy (evt) in acute ischemic stroke (ais) patients. and analysis the relationship between the dca damage degree and hemorrhage transformation (ht) and clinical outcome. patients: patients with ais caused by middle cerebral artery or internal carotid artery occlusion who accepted evt. dca examination: dca examinations were performed at 24 hours, 48 hours, 72 hours, and 5 days after evt. the objectives of the study were as follows: the changes of cerebral hemodynamics and parameters of dca in different time periods after evt were analyzed. so as to determine the correlation between hemodynamics and dca change and ht and clinical outcome after evt and to explore the predictors of ht and adverse clinical outcomes.

part of the data from march 2022 to march 2022 was obtained, but it was still need more data and need a one-year follow-up of the data. therefore, this is a 4 years prospective cohort study. the objectives of the study were as follows: this observational study was designed for observe the cerebral hemodynamics and dynamic cerebral autoregulation (dca) after endovascular thrombectomy (evt) in acute ischemic stroke (ais) patients. and analysis the relationship between the dca damage degree and hemorrhage transformation (ht) and clinical outcomes. to explore the predictors of ht and adverse clinical outcomes. a. to enroll 300 cases of patients with ais caused by middle cerebral artery or internal carotid artery occlusion who accepted evt. b. dca examinations were performed at 24 hours, 48 hours, 72 hours, and 5 days after evt. c. the computed tomography was performed to distinguish if the patients have ht within 7 days after evt. d. utilizing the modified rankin scale (mrs), the clinical prognosis was assessed 3 months and 1 year after stroke. the outcomes were dichotomized according to the mrs score: favorable outcome (mrs ≤ 2) and unfavorable outcome (mrs: 3-6). during the telephone call follow-up, the clinician was unaware of any pertinent clinical or dca information while examining each mrs score. e. all tests are non-invasive.

Eligibility criteria:
inclusion criteria: * (i) age ≥18 years; (ii) complete recanalization of the affected mca (thrombolysis in cerebral infarction grade 2b or 3); and (iii) sufficient temporal windows to obtain ﬂow signals for the mca. exclusion criteria: * (i) inability to perform dca after evt due to restlessness; (ii) re-occlusion of the culprit mca after evt; and (iii) other conditions such as low cerebral blood ﬂow caused by severe heart disease.

Keywords: acute ischemic stroke ultrasound endovascular thrombectomy dynamic cerebral autoregulation hemodynamics
5 day concomitant versus 10 day sequential therapy for eradication of h. pylori infection

Conditions: Helicobacter Pylori Infection

Summary: a five day quadruple concomitant therapy is as effective and safe as a 10 day sequential therapy for eradication of h. pylori infection.

the investigators studied 180 consecutive patients with h. pylori infection who were randomized to 5-day concomitant therapy (90 patients) and to 10-day sequential therapy (90 patients). 6 and 10 weeks after the end of therapy, patients were evaluated for their h. pylori status by 13c urea breath test. side effects and costs of either regimen were evaluated. in patients whose h pylori status at entry was assessed by endoscopy, culture was performed and antimicrobial resistance was determined

Eligibility criteria:
inclusion criteria: * h. pylori-infected patients who were at least 18 years of age and who had never received h. pylori eradication treatment were included in the study. exclusion criteria: * previous treatment for h. pylori infection, * use of inhibitors of acid secretion and/or antibiotics during the 6 weeks before the study, * gastrointestinal malignancy, * previous gastro-oesophageal surgery, * severe concomitant cardiovascular, * respiratory or endocrine diseases, * clinically significant renal or hepatic disease, * hematologic disorders, * any other clinically significant medical condition that could increase risk, * history of allergy to any of the drug used in the study, * pregnancy or lactation, * alcohol abuse, * drug addiction, * severe neurologic or psychiatric disorders, and * long-term use of corticosteroids or anti-inflammatory drugs.

Keywords: helicobacter pylori concomitant therapy sequential therapy levofloxacin
effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery

Conditions: Paralytic Ileus

Summary: postoperative ileus (poi) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (gi) tract following abdominal or non-abdominal surgery. dexamethasone \& dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries. previous study has shown that a single dose of dm before induction of anesthesia may be beneficial to reduce ileus for ibd by alleviating the postoperative systemic inflammatory response. perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability. the aim of this study is to compare the effect of preoperative intrathecal dexamethasone versus dexmedetomidine on paralytic ileus after major abdominal surgery.

postoperative ileus (poi) is considered as intolerance of oral intake due to disruption of the normal coordinated propulsive motor activity of the gastrointestinal (gi) tract following abdominal or non-abdominal surgery. dexamethasone \& dexmedetomidine have been reported to attenuate the incidence of paralytic ileus after abdominal surgeries. previous study has shown that a single dose of dm before induction of anesthesia may be beneficial to reduce ileus for ibd by alleviating the postoperative systemic inflammatory response. perioperative dexmedetomidine in major abdominal surgeries significantly decreased the time to flatus, defecation, and resuming normal diet, shortened length of stay, and improved haemodynamic stability.

Eligibility criteria:
inclusion criteria: * • age: 18-60 years. * sex: both males and females. * asa physical status: i and ii. * operation: open major abdominal surgery. * the surgery has to involve gastrointestinal resection and/or anastomosis. exclusion criteria: * • history of abnormal bowl habit or bowel obstruction * allergy to dexamethasone or dexmedetomidine * electrolyte disturbance * patient who receive any drugs known to influence gastrointestinal motility. * mental disorders or inability to cooperate * morbid obesity (bmi \> 40), pregnancy, lactation * diabetes * after neoadjuvant chemotherapy. * history of use of any steroids within the last 3 months * previous abdominal surgery, herniorrhaphy or unplanned secondary surgery

Keywords: major abdominal surgery
endoscopic peroral myotomy for treatment of achalasia

Conditions: Achalasia

Summary: this study intends to investigate the feasibility, safety and efficacy of peroral endoscopic myotomy for the treatment of achalasia in a multi center setting.

this study intends to investigate the feasibility, safety and efficacy of peroral endoscopic myotomy for the treatment of achalasia in a multi center s 70 patients will be enrolled to evaluate feasibility, safety and efficacy of peroral endoscopic myotomy. main outcome measurement is the eckardt symptom score at 3 month after peroral endoscopic myotomy. primary outcome: -eckhard symptom score 3 month after therapy. secondary outcomes: lower esophageal sphincter pressure at 3 month after therapy. reflux symptoms at 3 month after therapy. for this prospective study, inclusion criteria are achalasia, as diagnosed by established methods (contrast fluoroscopy, manometry, esophago-gastro-duodenoscopy) and age greater than 18 years. previous therapy, such as esophageal surgery or previous myotomy are exclusion criterion. a forward-viewing upper endoscope is used with a transparent distal cap attachment. carbon dioxide gas is necessary for insufflation during the procedures. an endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. a electrogenerator is used with spray coagulation mode. a coagulating forceps is used for hemostasis as needed. closure of the mucosal entry site is performed using standard endoscopic clips.

Eligibility criteria:
inclusion criteria: * patient with symptomatic achalasia and pre-op barium swallow, manometry and esophagogastroduodenoscopy which are consistent with the diagnosis * persons of age \> 18 years with medical indication for surgical myotomy or endoscopic balloon dilatation * signed written informed consent. exclusion criteria: * patients with previous surgery of the stomach or esophagus * patients with known coagulopathy * previous achalasia-treatment with surgery * patients with liver cirrhosis and/or esophageal varices * active esophagitis * eosinophilic esophagitis * barrett's esophagus * pregnancy * stricture of the esophagus * malignant or premalignant esophageal lesion * candida esophagitis * hiatal hernia \> 2cm

Keywords: achalasia heller myotomy dysphagia peroral endoscopic myotomy
using mhealth to optimize pharmacotherapy regimens

Conditions: Schizophrenia; First-Episode Psychosis

Summary: this project will use a smartphone technology to improve medication prescribing for individuals with fep. we will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team members with clinically relevant and time-sensitive information that will inform and promote shared decision making (sdm) and personalized interventions. the result will be a time-sensitive, data-driven, collaborative process to optimize medication regimens in order to maximize benefits, minimize harms, and promote adherence.

comprehensive early treatment of individuals experiencing schizophrenia has the potential to alter the course of illness and improve long-term outcomes. psychotropic medications are a critical component of early treatment strategies. first-episode psychosis (fep) is a critical time to optimize prescribing but evidence suggests that prescribing for this population is suboptimal. a contributing factor to these difficulties is thought to be the lack of accurate information about the effects of medications on symptoms, their side effects, as well as their behavioral, cognitive, and emotional correlates. at medication management appointments, prescribers typically rely on patients' recollection of how they were doing over periods of weeks. such retrospective assessments are problematic as they are vulnerable to the influence of memory difficulties, cognitive biases including recency effects and frequency illusions, and reframing. recent advances in smartphone technologies (mobile health; mhealth) may help to overcome many of the limitations of retrospective assessments. this pilot study will be a collaboration with ontrackny, an innovative coordinated specialty care (csc) program for individuals aged 16-30 who are experiencing fep. ontrackny originated as part of the nimh recovery after an initial schizophrenia episode (raise) implementation and evaluatoin study. the initial phase of this project will use input from stakeholders including patients, front-line providers, clinical leaders, and members of the research team to adapt and refine the mhealth intervention to improve feasibility and clinical utility. a pilot study at 3 ontrackny sites will then examine its feasibility and effectiveness by comparing the management and outcomes of 60 patients randomly assigned to the mhealth application or usual care.

Eligibility criteria:
inclusion criteria: * male or female ontrackny participants, ages 16 to 30, of any race/ethnicity * able and willing to give informed consent and participate in the intervention * participating in ontrackny for less than 1 year because this group may be more in need of medication adjustments and will be less likely to graduate from the program before 6 months of participation. exclusion criteria: * suicidal at baseline with c-ssrs score 4 or 5. * panss baseline score of 5 (moderately severe) or greater on the conceptual disorganization item (p2)

Keywords: mhealth schizophrenia ema
isometric training on blood pressure and on the autonomic modulation of hypertensive patients

Conditions: Hypertension

Summary: objective: analyze the effects of isometric handgrip exercise on arterial pressure and on the autonomic cardiac modulation of hypertensive individuals treated in the unified health system (uhs). intervention: patients were randomized into supervised group (sg) and control group (cg). sg will perform supervised isometric handgrip exercise for three weekly sessions in four sets with two minutes of isometric contraction with 30% of maximal voluntary contraction (mvc), in cg, individuals will be encouraged to increase their level of physical activity. measurements: blood pressure, autonomic modulation

the objective of this study is to analyze the effects of isometric handgrip exercise on arterial pressure and on the autonomic cardiac modulation of hypertensive individuals treated in the unified health system (uhs). two prospective, randomized, controlled trials will be conducted with hypertensive patients in the public health network of petrolina (pe) and são paulo (sp). included in the study will be individuals with an age group over 18 years of both genders, with systemic arterial hypertension (sah) controlled with the use of antihypertensive medication, non-smokers and without the presence of diabetes or other cardiovascular diseases that will be allocated randomly in two groups: supervised group (sg) and control group (cg). sg will be instructed to perform supervised isometric handgrip exercise for three weekly sessions in four sets with two minutes of isometric contraction with 30% of maximal voluntary contraction (mvc) of the subjects and interval between two-minute series. in cg, individuals will be encouraged to increase their level of physical activity. prior to initiation and after 12 weeks of intervention, blood pressure, autonomic cardiac modulation and level of physical activity will be obtained.

Eligibility criteria:
inclusion criteria: * it will include individuals with age range over 18 years of both genders and with controlled hypertension using antihypertensive medication and without the presence of diabetes or other cardiovascular diseases and who do not present high cardiovascular risk. exclusion criteria: * those individuals who: a) are diagnosed of diseases such as dyslipidemia, diabetes mellitus, cardiovascular or pulmonary diseases; b) adhere to another program of physical activities besides the training offered by the present study; c) change the class and dose of medication during the study; and d) aggravate the disease.

Keywords: hypertension hypotension cardiovascular system
point of care ultrasonography

Conditions: Respiratory Abnormalities; Cardiovascular Abnormalities; Hemodynamic Instability

Summary: this is a prospective, double-center, randomized clinical trial. the purpose of the trial is to evaluate the benefit of adding poc us to the management of inpatients admitted to the internal ward with respiratory, cardiovascular or hemodynamic abnormalities.

this is a prospective, double-center, randomized clinical trial. the purpose of the trial is to evaluate the benefit of adding poc us to the management of inpatients admitted to the internal ward with respiratory, cardiovascular or hemodynamic abnormalities. this is a stage 1 pilot trial aimed to provide better understanding on the study population and study groups. this trial will comprise a total of 60 patients, 30 subjects on the intervention group and an equal number on the control group. the results of this pilot trial will be to design a larger trial and calculate a required sample size.

Eligibility criteria:
inclusion criteria: 1. patients admitted to internal ward 2. age ≥ 18 3. no previous internal ward admission within the last 6 months 4. at least one symptom or sign of the following on admission: * respiratory abnormalities: dyspnea, rr\>20, o2 sat\<90% requirement of oxygen or non-invasive ventilation or mechanical ventilation * cardiovascular abnormalities: chest pain, hr\>100, new/worsening peripheral edema, newly diagnosed ecg changes * hemodynamic instability: sbp\<90 mmhg or on vasopressor infusion or pre-renal azotemia exclusion criteria: 1. patients with cognitive impairment or cannot sign informed consent. 2. subject enrolled in a different study 3. patients with end stage disease receiving palliative/end of life treatments. 4. pregnant patients. 5. patients that were given a consult by one of the research members pre enrollment 6. patient under responsibility of one of the study team members

Keywords: point of care ultrasonography soroka university medical center heart failure cardiovascular